Category: Press Release
-
Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer
BOSTON, March 12, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Colin Hayward, MBBS, FFPM, as the company’s Chief Medical Officer. Dr. Hayward brings more
-
Ratio Therapeutics has successfully dosed the first cohort in its Phase 1/2 study evaluating a novel FAP-targeted radiopharmaceutical in patients with late-stage aggressive sarcomas
BOSTON, MA, December 16, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that dosing of the first cohort has been completed in the ATLAS trial, a Phase
-
Ratio Therapeutics Announces the Appointment of Marcel Reichen as Chief Strategy Officer
BOSTON, November 4, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marcel Reichen, Ph.D., MBA, as the company’s Chief Strategy Officer. Dr. Reichen brings over
-
Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics
BOSTON and BELLEVUE, WA, June 20, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and TerraPower Isotopes, a subsidiary of TerraPower, a leading nuclear innovation company, today announced they entered
-
June 17th, 2025: Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals
BOSTON and WEST VALLEY CITY, Utah – June 17, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and Nusano, a physics company enabling breakthrough radioisotope supplies, today announced a
-
June 13, 2025: Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform
BOSTON, June 13, 2025 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics Inc. (Macrocyclics) exclusive manufacturing and distribution rights to Ratio’s
-
May 8th, 2025: Ratio Therapeutics to Establish New Radiopharmaceutical Manufacturing Facility
BOSTON, May 8, 2025 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced that it entered into an agreement with the Medical Innovation Technology Management division of Wasatch Group to
-
November 18th, 2024: Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Ratio to to receive upfront, and potential milestones and tiered royalty payments BOSTON, November 18, 2024 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license
-
June 20th, 2024: Ratio Therapeutics Announces the Appointment of Former Senator William Cowan to its Board of Directors
BOSTON, June 20, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Former U.S. Senator William “Mo” Cowan to its Board of Directors. Senator
-
May 6th, 2024: Ratio Therapeutics Announces the Appointment of Marc Becker as Chief Financial Officer and Chief Operating Officer
BOSTON, May 6, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marc Becker as the company’s Chief Financial Officer and Chief Operating Officer.